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Abstract
Background: Resistance to microtubule-stabilizing agents is a major hurdle for successful cancer therapy. We 
investigated combined treatment of microtubule-stabilizing agents (MSAs) with inhibitors of angiogenesis to overcome 
MSA resistance.
Methods: Treatment regimens of clinically relevant MSAs (patupilone and paclitaxel) and antiangiogenic agents (everolimus 
and bevacizumab) were investigated in genetically defined MSA-resistant lung (A549EpoB40) and colon adenocarcinoma 
(SW480) tumor xenografts in nude mice (CD1-Foxn1<nu>, ICRnu; 5–14 per group). Tumor growth delays were calculated by 
Kaplan-Meier analysis with Holm-Sidak tests. All statistical tests were two-sided.
Results: Inhibition of mTOR-kinase by everolimus only minimally reduced the proliferative activity of β tubulin–mutated 
lung adenocarcinoma cells alone and in combination with the MSA patupilone, but everolimus inhibited expression 
and secretion of vascular endothelial growth factor (VEGF) from these cells. mTOR-kinase inhibition strongly sensitized 
tumor xenografts derived from these otherwise MSA-resistant tumor cells to patupilone. Tumors treated with the 
combined modality of everolimus and patupilone had statistically significantly reduced tumor volume and stronger 
tumor growth delay (16.2 ± 1.01 days) than control- (7.7 ± 0.3 days, P = .004), patupilone- (10 ± 0.97 days, P = .009), and 
everolimus-treated (10.6 ± 1.4 days, P = .014) tumors. A combined treatment modality with bevacizumab also resensitized 
this MSA-refractory tumor model to patupilone. Treatment combination also strongly reduced microvessel density, 
corroborating the relevance of VEGF targeting for the known antivasculature-directed potency of MSA alone in MSA-
sensitive tumor models. Resensitization to MSAs was also probed in P glycoprotein–overexpressing SW480-derived tumor 
xenografts. Different bevacizumab regimens also sensitized this otherwise-resistant tumor model to clinically relevant 
MSA paclitaxel.
Conclusions: A treatment combination of MSAs with antiangiogenic agents is potent to overcome tumor cell–linked MSA 
resistance and should be considered as strategy for MSA-refractory tumor entities.
Microtubule-stabilizing agents (MSAs) belong to the most 
important classes of anticancer agents. Preventing the short-
ening of microtubules, they interfere with the dynamics of the 
microtubular network, which results in a transient or perma-
nent M-phase arrest and the induction of apoptotic cell death or 
mitotic catastrophe (1–4).
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Taxanes and epothilones are the clinically most relevant 
microtubule-stabilizing agents. Taxanes have been approved for 
a broad range of indications, including advanced breast cancer 
after failure of combination chemotherapy or at early relapse (5), 
high-grade ovarian cancer in combination with platinum com-
pounds, and primary treatment of non–small cell lung cancer 
in combination with cisplatin or carboplatin (6). Epothilones, 
which are structurally distinct from taxanes, may overcome 
some of their limitations suggesting a promising new treatment 
approach for cancer (7–9). Epothilones share the same binding 
site on β-tubulin with taxanes, albeit with different affinities 
and a slightly distinct mechanism of action. Several properties 
like increased water solubility, low susceptibility to common 
mechanisms of resistance, and the more tolerable toxicity pro-
file favor their development (10). Ixabepilone (Ixempra, Bristol 
Myers-Squibb) is the first approved compound in this class and 
is indicated as monotherapy or in combination with capecit-
abine for the treatment of patients with metastatic breast can-
cer (11).
Resistance to paclitaxel is linked to altered cellular β-tubulin 
isotype composition (12) and β tubulin–related mutations, which 
have been identified in tumor cell lines but also in the patient 
situation (13,14). A  major clinical hurdle represents tumor-
associated high expression of P glycoprotein–related multidrug 
resistance (MDR), which limits broad range application of taxa-
nes, but not of epothilones (10).
Tumor cells are the primary targets for classic anticancer 
treatment. Apart from their direct tumor cell–directed cyto-
toxicity, MSAs are also antiangiogenic and show antivascular 
effects (15–19). We and others previously demonstrated that 
MSAs downregulate the hypoxia-inducible factor (HIF)–tran-
scriptome and interfere with the secretion of multiple tumor 
cell–derived factors, eg, the major endothelial cell survival 
factor vascular endothelial growth factor (VEGF) and stress-
induced tissue inhibitors of matrix metalloproteinase (TIMP) 
(20–23). Thus, the tumor growth–inhibitory effect of MSAs 
in MSA-sensitive tumors might at least in part be because 
of their indirect, tumor cell–mediated effect on the tumor 
microenvironment.
The combined treatment modality of MSAs in combination 
with antiangiogenic agents was investigated in vitro and in 
vivo in preclinical MSA-sensitive tumor systems (24–29). At the 
same time, several clinical trials are ongoing combining differ-
ent classes of MSAs with inhibitors of angiogenesis (25,28,30). 
However, such a combined treatment modality might also rep-
resent an approach to overcome a tumor cell–linked treatment 
resistance to MSAs. Here we investigate a rationally designed 
combined treatment approach to overcome MSA resistances 
related to two distinct genetically defined resistance mecha-
nisms demonstrating that the microenvironment strongly 
determines the treatment response.
Methods
Compounds and Cell Cultures
Patupilone (epothilone B, EPO906) and Everolimus (RAD001) 
were provided by Novartis Pharma (Basel, Switzerland). For in 
vitro experiments, patupilone and everolimus were dissolved 
in DMSO (1 mM stock solution) and further diluted in serum-
containing medium. VEGF (Sigma, #V7259) was dissolved in H2O 
(1 mg/mL) and further diluted in serum-containing medium. 
A549, A549EpoB40, and SW480 cells were grown in RPMI 1640 
containing 10% fetal bovine serum, 1% penicillin-streptomycin, 
and 2 mM L-glutamine at 37°C in 5% CO2. Genotyped A549 and 
A549EpoB40 cells were a gift from Susan Band Horwitz (Albert 
Einstein College of Medicine, NY) and phenotypically tested for 
patupilone sensitivity. SW480 cells were obtained from ATCC. 
Human umbilical vein cells (HUVECs) were cultured in endothe-
lial growth medium (Promo Cell, #C-22210), supplemented with 
growth factors (PromoCell, C-39210#), 1% penicillin-streptomy-
cin at 37°C in 5% CO2.
Cell Proliferation Assay and Western Blot Analysis
The proliferative activity of tumor and endothelial cells was 
assessed with the colorimetric alamarBlue assay as described 
in detail in (15). Four western blot analysis cells were incu-
bated for 24 hours and one hour with patupilone and everoli-
mus, respectively, followed by incubation under normoxic or 
hypoxic conditions (0.2% pO2; Invivo2 400 hypoxia workstation, 
Biotrace International, Bridgend, UK) and cell lysis in lysis buffer 
(63mM Tris, 10% Glycerol, 2% SDS, pH 6.8 + DTT) and SDS-PAGE. 
Antibody detection was achieved by enhanced chemolumines-
cence (Amersham, Piscataway, NJ) using a polyclonal rabbit anti–
HIF-1α subunit antibody (Santa Cruz Biotechnology, #sc-10790, 
1:1000), a rabbit polyclonal anti–phospho-P70-S6kinase antibody 
(Cell Signalling Technology, #9205, 1:1000), a rabbit polyclonal 
anti–P70-S6kinase antibody (Cell Signalling Technology, #9202, 
1:1000) and a mouse monoclonal anti–β-actin antibody (Sigma 
Aldrich, #A5441, 1:1000). All experiments were carried out inde-
pendently at least three times.
RNA Extraction and Quantitative Real-Time 
Polymerase Chain Reaction
Sample RNA was isolated using an RNeasy Mini Kit (Qiagen) 
followed by reverse transcription and cDNA amplification 
using a High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems), and a FastStart Universal SYBR Green Master Mix 
(Roche) on an Applied Biosystems 7900HT real-time polymer-
ase chain reaction instrument. Gene expression values repre-
sent 2-ΔΔCt, normalized to GAPDH mRNA. The primers used were: 
VEGFA 5`-GAAGTGGTGAAGTTCATGGATGTCTAT-3` (forward) and 
5`-TCAGGGTACTCCTGGAAGATGTC-3` (reverse), GAPDH 5`- ACCC 
ACTCCTCCACCTTT-3` (forward), and 5`-CTCTTGTGCTCT TGC 
TGG-3` (reverse). All assays were performed in triplicates.
Enzyme-Linked Immunosorbent Assay
The concentration of VEGF levels in the filtered, conditioned 
media of A549EpoB40 cells was determined using the Quantikine 
Human VEGF Immunoassay kit (R&D Systems GmbH).
Tumor Xenografts
Tumor xenografts derived from A549, A549EpoB40, and SW480 
cells in athymic nude mice (5–14 per group) were generated 
as described in (15) and allowed to expand to a volume of 
200 mm3 (±10%) before treatment start and random assign-
ment. Patupilone (EPO906) was dissolved in 30% PEG-300/70% 
saline, and a single dose was applied intravenously at 2 mg/kg. 
Everolimus was diluted in 5% sucrose solution and administered 
p.o. at 2.5 mg/kg during five consecutive days. Bevacizumab 
(Avastin, Roche, concentrated infusion solution) was diluted 
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with saline and injected i.p. at 10 mg/kg twice (SW480) or three 
times (A549EpoB40). Paclitaxel (Taxol, Bristol-Myers Squibb, 
concentrated infusion solution) was diluted with saline and 
injected i.p. at 20 mg/kg. Control mice received a corresponding 
placebo treatment. This study was performed in strict accord-
ance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the Swiss Cantonal Veterinary 
Authorities.
Histology
Immunohistological endpoints were assessed as described 
in (15) for Ki-67 (rabbit clone SP6; dilution 1:100; NeoMarkers, 
Fremont, CA), CD31 (rabbit polyclonal, ab28364; dilution 1:50; 
Abcam, Cambridge, UK), and phospho-P70-S6Kinase (Cell 
Signalling Technology, #9202), using a Discovery immunohisto-
chemistry staining system (Ventana Medical Systems). Phospho-
P70-S6Kinase and Ki-67–positive tumor cells and amount of 
vessels (CD31) were counted in at least three randomly chosen 
visual fields (magnification 800x, 0.16mm2) in each xenograft 
(n = 3 for each group).
Statistical Analysis
In vitro data (VEGF expression and secretion analysis) were 
analyzed by one-way analysis of variance (ANOVA) on repli-
cate data. Pair-wise analyses were performed using the Tukey 
Test with relevant comparisons given in the text. Two different 
metrics were used to analyze in vivo treatment response data. 
Areas under the tumor volume curve (AUCs) were analyzed 
either by one-way ANOVA using the Tukey Test for pair-wise 
comparisons or ANOVA on ranks with the Dunn Test for pair-
wise comparison. Additionally, tumor growth delays were cal-
culated by Kaplan-Meier analysis with Holm-Sidak tests being 
used for pair-wise comparisons. Immunohistochemical data 
were analyzed by one-way ANOVA on replicate tumor samples 
(n = 6–9), and pair-wise analysis was performed using the Tukey 
Test. Relevant comparisons are given in the text and figures. All 
statistical tests were two-sided.
Results
We and others previously demonstrated that MSAs downregu-
late the HIF transcriptome and interfere with the secretion of 
multiple tumor cell–derived factors, eg, VEGF (20,21,23). The 
MSA-resistant A549EpoB40-derived tumor xenograft model 
was used to probe resensitization by interference with tumor-
derived growth factor secretion. A549EpoB40 cells contain a 
defined β-tubulin mutation and are up to 100 fold more resistant 
to classic MSAs such as epothilones and taxanes in comparison 
with their wild-type counterpart cells (A549) (8,15,31).
To probe VEGF expression and secretion in response to patu-
pilone, A549EpoB40 cells were treated for 24 hours with patu-
pilone at a concentration (0.2 nM) that was previously shown 
to downregulate the HIF transcriptome and subsequent VEGF 
expression in the corresponding A549 wild-type cells (15,23). 
As expected, VEGF expression and secretion was enhanced 
when A549EpoB40cells were kept under hypoxic conditions, but 
patupilone treatment did not affect VEGF expression and VEGF 
secretion under normoxic and hypoxic conditions in these MSA-
resistant cells (Figure 1, A and B).
Clinically relevant mTOR inhibitors decrease the expres-
sion and secretion of tumor-derived VEGF by inhibition of the 
mTOR-controlled HIF signal transduction cascade. The effect 
of the environment on VEGF expression and secretion was 
profound (normoxia vs hypoxia, P < .001). In contrast to patu-
pilone, the mTOR inhibitor everolimus potently reduced VEGF 
expression and secretion under both environmental conditions 
in A549EpoB40 cells (normoxia, controls vs everolimus, P < .001; 
hypoxia, controls vs everolimus, P < .001). Combined treatment 
with everolimus and patupilone reduced VEGF production as 
compared with controls but was not statistically different from 
everolimus treatment alone (Figure  1, A and B). Probing the 
activity of the mTOR downstream target P70-S6kinase dem-
onstrated that everolimus but not patupilone potently inhib-
ited mTOR activity under these conditions. In line with these 
results, hypoxia-dependent stabilization of the HIF-1α subunit 
was strongly counteracted in everolimus- but not in patupilone-
treated MSA-resistant A549EpoB40 cells (Figure 1C).
Effect of Patupilone, Everolimus, and Combined 
Treatment on Growth of A549EpoB40-Derived Tumor 
Xenografts
In vitro control experiments revealed that A549EpoB40 tumor 
cells were completely resistant to patupilone at a concentra-
tion (0.5 nM) that strongly reduced the proliferative capacity in 
A549 wild-type and other carcinoma cell lines (Figure  2A) (15). 
Treatment of A549EpoB40 cells with everolimus partially reduced 
their proliferative capacity at a concentration that strongly inhib-
ited mTOR activity (2.5 nM) (Figure 1C). However, no additive anti-
proliferative effect could be observed on combined treatment 
with patupilone (Figure 2A). To determine the treatment response 
to patupilone and everolimus alone and sensitization to patu-
pilone as part of a combined treatment modality in vivo, mice 
with A549EpoB40-derived MSA-resistant tumor xenografts were 
treated with everolimus (2.5 mg/kg/day) during five consecutive 
days and a single dose of patupilone (2 mg/kg, day 3) alone and 
in combination. Patupilone did not induce any growth inhibitory 
response in A549EpoB40-derived tumors (Figure  2B). Treatment 
with everolimus resulted in a minor but again not statistically 
significant change in tumor volume area under the curve (AUC) 
and tumor growth delay. Interestingly though, this minimal com-
bined treatment regimen of patupilone and everolimus resulted 
in a statistically significant reduction of AUC in these other-
wise patupilone-resistant tumors (combined 6317 ± 360 vs con-
trol 9525 ± 186, P < .05) (Figure 2B). Five out of six tumors treated 
with the combined treatment modality did not triple the initial 
tumor volume by the end of the observation time, demonstrat-
ing a potent and prolonged combined treatment effect of patu-
pilone and everolimus. Likewise a statistically significant tumor 
growth delay could also be observed at smaller tumor volumes. 
At the target tumor volume of 400 mm3, tumors treated with the 
combined modality of everolimus and patupilone had a statisti-
cally significantly stronger tumor growth delay (16.2 ± 1.01 days) 
than control- (7.7 ± 0.3 days, P = .004), patupilone- (10 ± 0.97 days, 
P = .009), and everolimus-treated (10.6 ± 1.4 days, P = .014) tumors, 
respectively, suggesting a positive interaction between patupi-
lone and everolimus (Figure 2C). Lack of a strong (supra)-additive 
effect in vitro corroborates that the treatment combination in 
vivo derives from an interplay between the tumor cell compart-
ment and the tumor microenvironment.
The combined treatment modality of patupilone and everoli-
mus was probed in parallel in tumors derived from β-tubulin 
wild-type A549 lung adenocarcinoma cells. These tumors 
showed increased sensitivity to everolimus, but more important 
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patupilone alone already induced a strong tumor growth delay, 
which was not further enhanced by the combined treatment 
with everolimus (Supplementary Figure 1, available online).
Effect of Patupilone, Bevacizumab, and Combined 
Treatment on Growth of A549EpoB40-Derived Tumor 
Xenografts
Downregulation of the HIF-transcriptome with subsequent 
reduction of tumor-derived VEGF expression could be exe-
cuted by the mTOR inhibitor everolimus instead of patupilone 
in MSA-resistant tumors (23,32). However, the mTOR inhibitor 
could also directly target endothelial cells. To specifically inves-
tigate the relevance of VEGF for resensitization of MSA-resistant 
tumors to patupilone, mice carrying tumor xenografts derived 
from A549EpoB40 cells were treated with patupilone in com-
bination with the αVEGF-inhibitory antibody bevacizumab. In 
vitro control experiments revealed that the proliferative capac-
ity of A549EpoB40 tumor cells was also not affected by patupi-
lone and bevacizumab alone and in combination (Figure  3A). 
A549EpoB40-derived tumors were completely resistant to patu-
pilone (1x2 mg/kg, day 3), whereas bevacizumab (3x10 mg/kg, 
Figure 1. Regulation of vascular endothelial growth factor (VEGF)–mRNA-expression (A) and VEGF secretion (B) by patupilone and everolimus. A549EpoB40 cells were 
treated with patupilone (0.2 nM, 24 hours) and/or everolimus (2.5 nM, one hour) and cultured under normoxic and hypoxic (0.2%) conditions. VEGF mRNA was deter-
mined 24 hours after starting hypoxic conditions by real-time polymerase chain reaction. Supernatants were collected and analyzed for VEGF protein levels by enzyme-
linked immunosorbent assay. Data are means of at least three independent experiments. Error bars represent standard deviations. C) Patupilone- and everolimus-
treated A549EpoB40 cell lysates were tested against the phosphorylated form of p70-S6Kinase and HIF-1α subunit by western blotting. Cells were preincubated with 
patupilone and everolimus for half an hour followed by additional incubation for four hours under normoxic or hypoxic conditions and cell lysis. Picture shows one 
representative experiment out of three experiments.
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day 1, 4, and 7)  induced a statistically significant reduction of 
tumor volume AUC (combined 8930 ± 921 vs control 12695 ± 2236, 
P = .016) (Figure 3B) in these tumors, as also observed for other 
tumor entities treated with such a minimal regimen of this 
antiangiogenic agent (33,34). Importantly, VEGF deprivation also 
sensitized for the MSA and combined treatment with patupilone 
resulted in an extended tumor growth delay in these otherwise 
patupilone-resistant tumors (AUC bevacicumab 8930 ± 921 vs 
bevacizumab plus patupilone 6453 ± 1580, P = .016; TGD, 400 mm3, 
bevacicumab 15.8 ± 1.36  days vs bevacizumab plus patupilone 
22.75 ± 1.63 days, P = .006) (Figure 3C). These results corroborate 
the results obtained by the combined treatment modality with 
everolimus and reinforce that tumor-derived survival factors, in 
particular VEGF, represent a major component of tumor resist-
ance to MSAs.
To determine the potency and a putative antiangiogenic 
effect of the different treatment modalities in situ, microves-
sel density (MVD), the level of phosphorylated P70-S6Kinase, 
and the proliferative status (Ki-67/MIB-1-positive cells) were 
determined in histological tumor sections (Figure  4, A-C). 
Tumors were collected 24 hours after the last treatment with 
everolimus and bevacizumab alone or in combination with 
patupilone. The level of phosphorylated P70-S6Kinase was 
reduced in response to everolimus (32.33 ± 3.05 positive cells/
visual field) by 65% in comparison with untreated control 
tumors (61.10 ± 2.20 positive cells/visual field), demonstrating 
the potency of the mTOR inhibitor (P = .001). The level of phos-
phorylated P70-S6kinase was not statistically significantly 
affected by cotreatment with patupilone or by treatment 
with patupilone alone, and, as expected, neither by bevaci-
zumab nor by bevacizumab in combination with patupilone 
(Figure  4A). The proliferative activity of the MSA-resistant 
tumors was not reduced by patupilone. On the other hand, all 
other treatment modalities statistically significantly reduced 
the proliferative activity to comparable extents, which cor-
responds to the antiproliferative activity of most of these 
treatment modalities at this early time point after treatment 
start (P < .001) (Figure 4C). Interestingly, the microvessel den-
sity was strongly reduced down to 37% and 30% of control, 
when patupilone was used in combination with everolimus 
and bevacizumab, respectively (control 44.8 ± 8.4 MV/visual 
field vs patupilone plus everolimus 17.3 ± 2.3 MV/visual field, 
Figure 2. Combined treatment of patupilone-resistant lung adenocarcinoma cells and tumor xenografts with patupilone and everolimus. A) Antiproliferative effect of 
patupilone (0.5 nM) and everolimus (2.5 nM) in vitro. Data are means from three independent experiments. Error bars represent standard deviations. B) Tumor growth 
delay of A549EpoB40-derived tumor xenografts (5–14 per group, as indicated in the figure) in response to combined treatment with patupilone (2 mg/kg, one applica-
tion) and everolimus (2.5 mg/kg, during five consecutive days). Error bars represent standard deviations. P values determined by two-sided analysis of variance using 
the Tukey Test for pair-wise comparisons. C) Kaplan-Meier curves for tumors reaching 400 mm3 tumor volume. Tumor growth delays were calculated by Kaplan-Meier 
analysis with Holm-Sidak tests being used for pair-wise comparisons. All statistical tests were two-sided.
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Figure 4. Response to treatment with patupilone, everolimus, and bevacizumab alone and in combination. A) Microvessel density. B) mTOR activity. C) Tumor cell 
proliferation. Mice carrying A549EpoB40-derived xenografts (n = 3 per group) were treated as described, and tumors were collected 24 hours after the last treatment 
with everolimus and bevacizumab alone or in combination with patupilone. Tumors from patupilone alone–treated mice were collected 24 hours after the last dose 
of the corresponding combined treatment modality. Tumors were harvested, formalin fixed and stained for CD31, phospho-P70-S6Kinase, and MIB1/Ki-67. Error bars 
represent standard deviations. Data were analyzed by one-way analysis of variance on replicate tumor samples (n = 6–9), and pair-wise analysis was performed using 
the Tukey Test. Relevant comparisons are given in the text and figures. All statistical tests were two-sided. MVD = microvessel density.
Figure 3. Combined treatment of patupilone-resistant lung adenocarcinoma cells and tumor xenografts with patupilone and bevacizumab. A) Antiproliferative effect 
of patupilone (0.2 nM) and bevacizumab (50 µg/mL) in vitro. Data are means from three independent experiments. Error bars represent standard deviations. B) Tumor 
growth delay of A549EpoB40-derived tumor xenografts (n = 5–6 per group) in response to combined treatment with patupilone (2 mg/kg, one application) and bevaci-
zumab (3x10 mg/kg). Error bars represent standard deviations. P values were determined by two-sided analysis of variance using the Tukey Test for pair-wise compari-
sons. C) Kaplan-Meier curves for tumors reaching 400 mm3 tumor volume. Tumor growth delays were calculated by Kaplan-Meier analysis with Holm-Sidak tests being 
used for pair-wise comparisons All statistical tests were two-sided.
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P = .03; patupilone plus bevacizumab 13.5 ± 3.5 MV/visual 
field, P = .004) (Figure 4A). Strong morphological changes with 
almost crumbled and destructed vessels were only observed 
in response to the combined treatment modalities (patupilone 
plus everolimus and patupilone plus bevacizumab, respec-
tively). Representative tumor sections depict microvessel den-
sity, mTOR activity and tumor cell proliferation in response to 
treatment (Figure 5). These results suggest a positive antian-
giogenic interaction between the MSA and everolimus and 
bevacizumab, respectively, in these MSA-resistant tumors. 
Additional in vitro experiments also demonstrated a VEGF-
protective effect on endothelial cells towards patupilone. 
Pretreatment of endothelial cells with bevacizumab again 
resensitized these cells to the MSA (Supplementary Figure 2, 
available online).
Effect of Paclitaxel, Bevacizumab, and Combined 
Treatment on Growth of PgP-Overexpressing 
SW480-Derived Tumor Xenografts
While A549EpoB40 cells carry a specific mutation in the MSA-
binding region of β-tubulin, leading to patupilone and taxane 
resistance, many tumors overexpress the multidrug resistance 
(MDR)–related efflux pump P-glycoprotein, thereby strongly 
reducing the potency of P-glycoprotein substrates such as 
taxanes (35). We probed the strategy to combine MSAs with 
inhibitors of angiogenesis also in a carcinoma tumor model 
(SW480), which is MSA resistant because of PgP-overexpression 
(31). Control in vitro experiments confirmed that these colon 
adenocarcinoma cells are completely resistant to paclitaxel and 
bevacizumab (Figure 6A). SW480-derived tumor xenografts were 
completely resistant to treatment with paclitaxel alone (20 mg/
kg, day 3) while bevacizumab (2x5 mg/kg, day 1 and 4) induced 
a partial tumor growth delay (to double tumor volume control 
10.60 ± 1.70  days vs bevacizumab 15.80 ± 2.71  days, P = .003). 
Similar to the treatment response observed in the lung carci-
noma tumor model (see above), a combined treatment modal-
ity of paclitaxel in combination with bevacizumab also induced 
a statistically significant tumor growth delay in this otherwise 
paclitaxel-resistant tumor model (bevacizumab 15.80 ± 2.71 days 
vs bevacizumab plus paclitaxel 24.4 ± 5.28 days, P = .013). Tumors 
did not even double their tumor volume over the entire obser-
vation time of 25  days in response to this minimal combined 
treatment regimen (Figure  6, B and C). A  comparable strong 
treatment response was observed when tumors were treated 
with a different treatment regimen of bevacizumab (1x10 mg/kg) 
in combination with paclitaxel (20 mg/kg) (see Supplementary 
Figure 3, available online). These results, obtained in a β-tubulin-
mutation-unrelated, additional MSA–resistant tumor model, 
confirm the potency of a combined treatment modality of MSA 
and inhibitors of angiogenesis against otherwise MSA-refractory 
tumors.
Figure 5. Representative tumor sections depicting microvessel density, high magnification images of representative vessels, mTOR activity, and tumor cell proliferation 
in response to treatment. Mice carrying A549EpoB40-derived xenografts (n = 3 per group) were treated as described, and tumors were collected 24 hours after the last 
treatment with everolimus and bevacizumab alone or in combination with patupilone. Tumors from patupilone alone–treated mice were collected 24 hours after the 
last dose of the corresponding combined treatment modality. Tumors were harvested, formalin fixed and stained for CD31, phospho-P70-S6Kinase, and MIB1/Ki-67. 
Arrows indicate microvessels. Scale bars for all pictures correspond to 100 µm.
8 of 10 | JNCI J Natl Cancer Inst, 2015, Vol. 107, No. 4
a
r
t
ic
le
Discussion
Resistance to microtubule-stabilizing agents is a major hurdle 
for successful cancer therapy. MSAs have a tumor cell–directed 
but also a major tumor vasculature–directed effect. Our own 
previous and novel results have demonstrated that potent anti-
vascular targeting still depends on the interference of MSAs 
with the functional microtubular network in tumor cells (15,23). 
Intrinsic or acquired cell resistance to MSAs on the tumor cell 
level subsequently also abrogates its antivascular potency. 
Therefore, a combined treatment modality of MSA with an 
antiangiogenic, VEGF-reducing agent could overcome a tumor 
cell–based intrinsic MSA resistance in vivo and reestablish its 
potent antivascular effect.
We mechanistically investigated this concept in two tumor 
models that are MSA resistant either because of a tumor cell–spe-
cific β-tubulin mutation or the overexpression of the multidrug 
resistance–related efflux pump P-glycoprotein. Tubulin mutations 
and PgP overexpression are both of clinical relevance and hamper 
the broader use of MSAs as a first-line therapeutic option, eg, for 
MDR-overexpressing colon carcinoma or for metastatic breast 
cancer. We previously determined that a combined treatment 
modality of patupilone with a broad-range cytotoxic agent could 
not overcome patupilone resistance in these highly MSA-resistant 
tumors. Interestingly, we now demonstrate that specific down-
regulation of proangiogenic VEGF signaling by mTOR inhibition 
or VEGF neutralization with clinically approved agents strongly 
resensitizes these patupilone-resistant lung-adenocarcinoma 
cell-derived tumors to patupilone. Likewise taxane-resistant 
colon carcinomas, which are MDR overexpressing, were resensi-
tized upon VEGF deprivation. A combined treatment modality of 
taxane with the mTOR inhibitor everolimus was not investigated 
in the colon carcinoma tumor model since everolimus is also a 
substrate for the P-glycoprotein efflux pump (36). Our own in vitro 
results corroborated that everolimus is a P-glycoprotein substrate 
(Supplementary Figure 4, available online).
Several preclinical studies have reported on the promis-
ing combined treatment of MSAs with mTOR inhibitors, and 
enhanced activity could be linked to increased tumor cell apop-
tosis. However, these studies and combined treatment modali-
ties including MSAs with bevacizumab were solely performed 
in tumor cell systems and tumor xenografts that were already 
responsive to patupilone or taxanes alone and were not charac-
terized as MSA refractory. Likewise, several clinical trials were 
conducted with related combined treatment modalities against 
multiple tumor entities and demonstrated feasibility with prom-
ising activity, but none of these trials stratified along known MSA 
resistances (25,28,30). In particular, the efficacy of paclitaxel plus 
Figure 6. Combined treatment of paclitaxel-resistant SW480 colon adenocarcinoma cells and tumor xenografts with patupilone and bevacizumab. A) Antiproliferative 
effect of paclitaxel (50 nM) and bevacizumab (50 µg/mL) in vitro. Data are means from three independent experiments. Error bars represent standard deviations. B) 
Tumor growth delay of SW480-derived tumor xenografts (n = 5–9 per group) in response to combined treatment with paclitaxel (20 mg/kg, one application) and bevaci-
zumab (2x5 mg/kg). Error bars represent standard deviations. P values were determined by two-sided analysis of variance using the Tukey Test for pair-wise compari-
sons. C) Kaplan-Meier curves for tumors reaching 400 mm3 tumor volume. Tumor growth delays were calculated by Kaplan-Meier analysis with Holm-Sidak tests being 
used for pair-wise comparisons. All statistical tests were two-sided.
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bevacizumab was compared with paclitaxel alone for metastatic 
breast cancer and revealed prolonged progression-free survival 
(primary endpoint) but not overall survival. However, this phase III 
trial also did not stratify for MSA resistances (30). Resensitization 
by the antiangiogenic agent might only manifest in MSA-resistant 
but not in MSA-responsive cases. Likewise we could not observe 
enhanced potency of the combined treatment modality (patupi-
lone with everolimus) in patupilone-sensitive tumor xenografts. 
Interestingly, a case study has recently reported on resensitiza-
tion of a paclitaxel-resistant metastatic breast cancer patient to 
paclitaxel therapy by additional bevacizumab treatment, sup-
porting the results investigated in our study (37).
The strong treatment responses to a minimal combined 
treatment regimen of MSAs with bevacizumab in otherwise 
patupilone- and paclitaxel- completely refractory tumors mech-
anistically demonstrate that indeed VEGF as survival factor 
abrogates the primarily antivascular-directed and eventually 
strong tumor controlling effect of MSAs. In tumors derived from 
patupilone- and paclitaxel-sensitive tumor cells, the MSAs suc-
cessfully diminish VEGF secretion by microtubule interference 
and thereby prime the tumor for their antivasculature activity 
on their own. Our immunohistochemical analysis further sup-
ports that the combined treatment modality initially affects 
the tumor vasculature. It is primarily the microvessel density 
and not the proliferative activity of tumor cells that is initially 
reduced upon combined treatment in tumor xenografts derived 
from MSA-resistant tumor cells.
This study also had some limitations. As efficacy-oriented end-
points we determined increase of tumor volume over time and 
absolute tumor growth delay in response to treatment, comple-
mented by relevant mechanistic experiments. Tumor control as an 
additional efficacy-oriented endpoint could further illustrate the 
potency of these combined treatment modalities to overcome MSA 
resistances. Furthermore it will be of interest to validate this treat-
ment modality also in orthotopic MSA-resistant tumor models, 
thereby identifying also putative additional microenvironmental 
factors that might codetermine treatment outcome.
Overall, our results demonstrate that the interaction 
between the tumor cell compartment and the tumor microenvi-
ronment strongly determines the treatment response to differ-
ent microtubule-stabilizing agents. More important, a combined 
treatment modality of MSAs with antiangiogenic agents could 
overcome tumor cell–linked MSA resistance and should be fur-
ther considered as clinical strategy for MSA-refractory tumor 
entities with intrinsic or acquired resistance mechanisms.
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